Annovis Bio Inc ANVS 深 沪

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

Annovis Bio, a Phase 3 clinical-stage biotechnology company, announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer. Dr. Fang, who joined the company in 2021, will lead scientific strategy and research operations for its Alzheimer's disease (AD) and Parkinson's disease (PD) programs. This promotion comes as the company advances its lead drug candidate, buntanetap, toward pivotal Phase 3 AD study data and NDA submission. Dr. Fan...

07-01 12:00

Annovis Bio Regains NYSE Listing Compliance

Annovis Bio, a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases, has regained compliance with New York Stock Exchange (NYSE) continued listing standards. The company was previously notified of non-compliance due to its market capitalization and stockholders' equity falling below $50 million. Annovis implemented corrective actions and restored compliance ahead of the 18-month deadline. The company r...

05-26 12:00

Why 8x8 Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

Shares of 8x8 Inc (NASDAQ: EGHT) jumped 13.3% in pre-market trading after reporting better-than-expected Q4 results, with adjusted earnings of 11 cents per share and revenue of $185.25 million. GCL, PETZ, WOK, MEHA, HAO, TDIC, FEED, KELYA, and AMC were among the top gainers, while RUBI, AMIX, IPW, ANVS, and WGRX were among the top losers in pre-market trading.

05-20 16:31

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Co-Diagnostics (NASDAQ:CODX) shares rose 20.8% to $2.38 during Tuesday...

05-20 05:06

Annovis Bio shares are trading lower after the company announced a $250 million public offering.

Annovis Bio shares are trading lower after the company announced a $250 million...

05-20 04:24

Annovis Bio Q1 EPS $(0.63) Misses $(0.40) Estimate

Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.40) by 61.54 percent. This is a 96.88 percent decrease over losses of $(0.32) per share from the

05-15 19:38

Annovis Bio Q1 FY26 net loss widens to $17.61 million

Annovis Bio Q1 FY26 net loss widens to $17.61 million Annovis Bio posted a net loss of USD 17.61 million, or USD 0.63 per share, for first-quarter 2026, widening from a net loss of USD 5.54 million, or USD 0.32 per share, a year earlier. Research and development expense more than doubled to USD 16.

05-15 19:32

Annovis Bio Announces New Publication Titled Buntanetap Treatment In Mild To Moderate Alzheimer's Disease: Phase 2/3 Study In Peer-Reviewed Journal Nature NPJ Dementia

Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and well-tolerated, including in

04-28 20:10

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

04-28 12:00

Annovis Bio shares are trading lower after the company announced pricing of its $10 million offering of common stock and warrants.

Annovis Bio shares are trading lower after the company announced pricing of its...

04-09 22:31